Liau Jau-Yu, Lee Jen-Chieh, Tsai Jia-Huei, Yang Ching-Yao, Liu Tsung-Lin, Ke Zhi-Long, Hsu Hung-Han, Jeng Yung-Ming
Department of Pathology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Mod Pathol. 2015 Dec;28(12):1545-54. doi: 10.1038/modpathol.2015.114. Epub 2015 Oct 2.
According to cytogenetic aberrations, sarcomas can be categorized as complex or simple karyotype tumors. Alternative lengthening of telomeres is a telomere-maintenance mechanism common in sarcomas. Recently, this mechanism was found to be associated with loss of either α-thalassemia/mental retardation syndrome X-linked (ATRX) or death domain-associated (DAXX) protein. We previously reported that alternative lengthening of telomeres and loss of ATRX expression were common in leiomyosarcoma, angiosarcoma, pleomorphic liposarcoma, and dedifferentiated liposarcoma. In the present study, we screened an additional 245 sarcomas of other types to determine the prevalence of alternative lengthening of telomeres, loss of ATRX/DAXX expression, and their relationship. Undifferentiated pleomorphic sarcomas were frequently alternative lengthening of telomeres positive (65%) and loss of ATRX was seen in approximately half of the alternative lengthening of telomeres-positive tumors. Nineteen of 25 myxofibrosarcomas were alternative lengthening of telomeres-positive, but only one was ATRX deficient. Three of 15 radiation-associated sarcomas were alternative lengthening of telomeres positive, but none of them was ATRX deficient. Alternative lengthening of telomeres and/or loss of ATRX were uncommon in malignant peripheral nerve sheath tumors, gastrointestinal stromal tumors, and embryonal rhabdomyosarcomas. By contrast, none of the 71 gene fusion-associated sarcomas was ATRX deficient or alternative lengthening of telomeres positive. All tumors exhibited preserved DAXX expression. Combining our previous studies and this study, a total of 384 sarcomas with complex karyotypes were examined, 83 of which were ATRX deficient (22%). By telomere-specific fluorescence in situ hybridization, 45% (138/308) were alternative lengthening of telomeres positive, 55% (76/138) of which were ATRX deficient. Loss of ATRX was highly associated with alternative lengthening of telomeres (P<0.001). We conclude that alternative lengthening of telomeres is a frequent telomere-maintenance mechanism in cytogenetically complex sarcomas. Loss of ATRX is highly associated with this feature.
根据细胞遗传学异常,肉瘤可分为复杂核型或简单核型肿瘤。端粒替代延长是肉瘤中常见的一种端粒维持机制。最近,发现这种机制与X连锁的α地中海贫血/智力发育迟缓综合征(ATRX)蛋白或死亡结构域相关蛋白(DAXX)的缺失有关。我们之前报道过,端粒替代延长和ATRX表达缺失在平滑肌肉瘤、血管肉瘤、多形性脂肪肉瘤和去分化脂肪肉瘤中很常见。在本研究中,我们对另外245例其他类型的肉瘤进行了筛查,以确定端粒替代延长、ATRX/DAXX表达缺失的发生率及其关系。未分化多形性肉瘤端粒替代延长阳性率较高(65%),约一半端粒替代延长阳性的肿瘤存在ATRX缺失。25例黏液纤维肉瘤中有19例端粒替代延长阳性,但只有1例ATRX缺陷。15例辐射相关肉瘤中有3例端粒替代延长阳性,但均无ATRX缺陷。端粒替代延长和/或ATRX缺失在恶性外周神经鞘瘤、胃肠道间质瘤和胚胎性横纹肌肉瘤中不常见。相比之下,71例基因融合相关肉瘤均无ATRX缺陷或端粒替代延长阳性。所有肿瘤均表现出DAXX表达保留。结合我们之前的研究和本研究,共检测了384例复杂核型肉瘤,其中83例(22%)存在ATRX缺陷。通过端粒特异性荧光原位杂交,45%(138/308)端粒替代延长阳性,其中55%(76/138)ATRX缺陷。ATRX缺失与端粒替代延长高度相关(P<0.001)结论是,端粒替代延长是细胞遗传学复杂的肉瘤中常见的端粒维持机制。ATRX缺失与这一特征高度相关。